{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:07Z","timestamp":1786991227653,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacig.2025.100501","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:04:28Z","timestamp":1748433868000},"page":"100501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of hypereosinophilic syndromes in the United States: Patients\u2019 perspective"],"prefix":"10.1016","volume":"4","author":[{"given":"Jared","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kovalszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gratie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G.","family":"Edgecomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2025.100501_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2025.100501_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13601-019-0277-4","article-title":"Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm","volume":"9","author":"Leru","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jacig.2025.100501_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacig.2025.100501_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2025.100501_bib9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacig.2025.100501_bib10","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.jaip.2020.04.069","article-title":"Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported outcomes tool","volume":"8","author":"Kovacs","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular manifestations of hypereosinophilic syndromes","volume":"27","author":"Ogbogu","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2025.100501_bib12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bjhh.2016.11.008","article-title":"Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay","volume":"39","author":"Neto","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.jacig.2025.100501_bib14","article-title":"Insights from social media on the patient experience of living with rare eosinophil-driven diseases","volume":"9","author":"Strobel","year":"2022","journal-title":"J Patient Exp"},{"key":"10.1016\/j.jacig.2025.100501_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/17460441.2015.1037271","article-title":"Exploring open innovation with a patient focus in drug discovery: an evolving paradigm of patient engagement","volume":"10","author":"Allarakhia","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jacig.2025.100501_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840974","article-title":"Association between baseline therapy and flare reduction in mepolizumab-treated patients with hypereosinophilic syndrome","volume":"13","author":"Reiter","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib17","series-title":"Voice of the patient report: hypereosinophilic syndromes","author":"Strobel","year":"2019"},{"key":"10.1016\/j.jacig.2025.100501_bib21","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.anai.2022.08.998","article-title":"Patients\u2019 perspective on the burden of hypereosinophilic syndrome","volume":"129","author":"Silver","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib22","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.jaip.2020.04.025","article-title":"Single-organ and multisystem hypereosinophilic syndrome patients with gastrointestinal manifestations share common characteristics","volume":"8","author":"Kuang","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib23","series-title":"Work experience of the population\u20142021. Bureau of Labor Statistics","year":"2022"},{"key":"10.1016\/j.jacig.2025.100501_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","author":"Kuang","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2025.100501_bib26","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100501_bib31","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jacig.2025.100501_bib32","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.jaip.2023.07.026","article-title":"Biologics and hypereosinophilic syndromes: knowledge gaps and controversies","volume":"11","author":"Kuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2025.100501_bib33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2025.100501_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000975660.56238.59","article-title":"Pb2229: a phase 3 study evaluating the efficacy and safety of benralizumab in patients with hypereosinophilic syndrome","volume":"7","author":"Ogbogu","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.jacig.2025.100501_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MAJ.0b013e318169569a","article-title":"Successful treatment of hypereosinophilic syndrome with cyclosporine","volume":"337","author":"Donald","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jacig.2025.100501_bib38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.intimp.2013.04.033","article-title":"Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome","volume":"16","author":"Tabata","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jacig.2025.100501_bib39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.17615","article-title":"Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis","volume":"195","author":"Williams","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932500102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932500102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:23:05Z","timestamp":1762647785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277282932500102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S277282932500102X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100501","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of hypereosinophilic syndromes in the United States: Patients\u2019 perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100501"}}